Fortress Biotech Inc Stock Price, News & Analysis

Journey Medical Corporation announced new data analysis from Phase 3 trials of Emrosi (DFD-29) for treating moderate-to-severe papulopustular rosacea will be presented at SDPA 2025. The analysis showed Emrosi's efficacy is independent of patient body weight, based on two trials (MVOR-1 and MVOR-2) with 653 total participants. The drug demonstrated superior efficacy compared to both placebo and doxycycline, with success rates up to 75.5% in IGA treatment outcomes. As the lowest FDA-approved oral minocycline dose that doesn't require weight-based adjustments, Emrosi showed significant improvements in inflammatory lesion counts across all weight categories while maintaining a favorable safety profile.

Journey Medical Corporation announced that its FDA-approved rosacea treatment Emrosi was featured on Lifetime TV's 'The Balancing Act'. The segment, which premiered on June 9, 2025, and will be rebroadcast on June 19, showcases Emrosi, a 40 mg Minocycline Hydrochloride Modified-Release Capsule treatment for inflammatory rosacea lesions in adults. The feature included expert insights from Dr. Saurabh Lodha of Pura Dermatology, highlighting Emrosi's unique formulation as the lowest-dose oral minocycline available. The treatment, FDA-approved in November 2024, is available by prescription at specialty pharmacies and represents what the company believes could be a paradigm shift in rosacea treatment.

Fortress Biotech (NASDAQ: FBIO) has completed the sale of its subsidiary Checkpoint Therapeutics to Sun Pharmaceutical Industries Limited. The transaction, which closed on May 30, 2025, will provide Fortress with approximately $28 million in immediate proceeds, plus potential additional benefits including a contingent value right (CVR) of up to $4.8 million and a 2.5% royalty on future net sales of UNLOXCYT. The deal values Checkpoint shares at $4.10 per share in cash, with stockholders eligible for an additional $0.70 per share through the CVR if UNLOXCYT receives approval in key European markets. UNLOXCYT, approved by the FDA in December 2024, is the first FDA-approved PD-L1 blocking antibody for advanced cutaneous squamous cell carcinoma. Fortress is now focusing on other initiatives, including their subsidiary Cyprium Therapeutics' CUTX-101 with a PDUFA date of September 30, 2025.

Fortress Biotech (FBIO) reported Q1 2025 financial results and corporate highlights. Key developments include: Emrosi™ commercial launch for rosacea treatment, pending acquisition of subsidiary Checkpoint Therapeutics by Sun Pharma (~$28M expected at closing), and FDA's acceptance of CUTX-101's New Drug Application for priority review with PDUFA date of September 30, 2025. Q1 financials show consolidated cash of $91.3M (up from $57.3M in Q4 2024), net product revenue of $13.1M, and net loss of $(12.7M) or $(0.48) per share. R&D expenses decreased to $3.9M from $24.8M year-over-year, while SG&A costs increased to $25.7M from $17.9M. The company's pipeline includes multiple late-stage programs and newly approved products, positioning it for continued growth and potential monetization opportunities.

Journey Medical Corporation (NASDAQ: DERM) reported its Q1 2025 financial results, highlighting total net product revenues of $13.1 million, consistent with $13.0 million in Q1 2024. The company successfully launched Emrosi™, their new oral rosacea treatment, contributing $2.1 million in incremental revenue. The company's gross margin improved to 64% from 54% year-over-year.

Key financial metrics include a reduced net loss of $4.1 million ($0.18 per share) compared to $10.4 million ($0.53 per share) in Q1 2024. Cash position strengthened to $21.1 million as of March 31, 2025. The company reported no R&D costs in Q1 2025, down from $7.9 million in Q1 2024, while SG&A expenses increased by $2.1 million due to Emrosi launch activities.

Notable achievements include the publication of Emrosi's Phase 3 trial results in JAMA Dermatology, showing superiority over Oracea® and placebo, and its inclusion in the National Rosacea Society's Treatment Algorithms.

Checkpoint Therapeutics (NASDAQ: CKPT) announced its Q1 2025 financial results and significant corporate updates. The company achieved a major milestone with the FDA approval of UNLOXCYT™ (cosibelimab-ipdl) in December 2024, becoming the first and only PD-L1 blocking antibody approved for treating advanced cutaneous squamous cell carcinoma. In March 2025, Checkpoint entered into a merger agreement with Sun Pharmaceutical Industries, valued at up to $416 million, with the special stockholder meeting scheduled for May 28, 2025.

Financial highlights for Q1 2025 include: cash position increased to $33.0 million from $6.6 million in Q4 2024; R&D expenses decreased to $3.8 million from $8.5 million year-over-year; G&A expenses increased to $7.4 million from $2.5 million; and net loss was $11.2 million ($0.19 per share) compared to $10.9 million ($0.33 per share) in Q1 2024.

Journey Medical Corporation (NASDAQ: DERM), a commercial-stage pharmaceutical company focused on marketing FDA-approved dermatological treatments, has scheduled its first quarter 2025 financial results announcement for May 14, 2025, after U.S. market close.

The company will host a conference call and audio webcast at 4:30 p.m. ET on the same day. U.S. participants can dial 1-866-777-2509, while international callers should use 1-412-317-5413. The webcast will be accessible through Journey Medical's website and will remain available for approximately 30 days after the call.

Fortress Biotech (NASDAQ: FBIO), a biopharmaceutical company focused on acquiring and advancing assets for shareholder value through product revenue, equity holdings and dividend and royalty revenue, has announced its participation in the H.C. Wainwright 1st Annual Royalty Company Virtual Conference on May 13, 2025.

The company's CEO, Lindsay A. Rosenwald, M.D., will participate in two sessions: a Fireside Chat from 2:00 PM to 2:30 PM ET, and a Panel Presentation titled "Development Stage Companies – Where Do Royalty and Tech Platform Plays Fit?" from 5:00 PM to 6:00 PM ET.

Journey Medical (NASDAQ: DERM) has promoted Ramsey Alloush from General Counsel to Chief Operating Officer (COO), while maintaining his General Counsel position. Alloush, who joined the company in 2020, brings over 15 years of pharmaceutical industry experience.

During his tenure at Journey Medical, Alloush has played a important role in navigating regulatory landscapes, managing financing transactions including the company's 2021 IPO, and overseeing acquisitions and licensing. His background includes experience at the Securities and Exchange Commission and Medicis Pharmaceuticals' Aesthetics Division.

The appointment comes at a strategic time as Journey Medical prepares for the launch of Emrosi™, a new dermatological treatment. The company focuses on marketing FDA-approved prescription pharmaceutical products for dermatological conditions.